

Editor

Leo van de Putte (The Netherlands)

Associate Editors

Thomas Bardin (France)
Johannes Bijlsma (The Netherlands)
Gerd Burmester (Germany)

Bevrah Hahn (USA)
Frank Wollheim (Sweden)
Anthony Woolf (UK)

Methodological Adviser

Jaap Fransen (The Netherlands)

Editorial Board

M Aringer (Austria)
P Bacon (UK)
F Berenbaum (France)
M Boers (The Netherlands)
D Boumpas (Greece)
B Bresnihan (Ireland)
H Capell (UK)
M Cutolo (Italy)
G Firestein (USA)
P Goupille (France)
E Gravalles (USA)
W Gross (Germany)
F Guillemin (France)
G Herrero-Beaumont (Spain)
F Houssiau (Belgium)
T Huizinga (The Netherlands)
C Jorgensen (France)
G Kollias (Greece)
T Kvien (Norway)
M Leirisalo-Repo (Finland)
F Luijten (Belgium)
H-M Lorenz (Germany)
W Maslinski (Poland)
M Maticci Cerinic (Italy)

K Nishioka (Japan)
M Nurmohamed (The Netherlands)
S Özen (Turkey)
T Pap (Germany)
E Pascual Gómez (Spain)
L Punzi (Italy)
L Rönnblom (Sweden)
B Rozman (Slovenia)
G Schett (Austria)
J Da Silva (Portugal)
H Schulze-Koops (Germany)
A So (Switzerland)
T Sokka (USA)
D Symmons (UK)
P-P Tak (The Netherlands)
A Tyndall (Switzerland)
A Tzioufas (Greece)
J Vencovsky (Czech Republic)
M Ward (USA)
M Weisman (USA)
H Yazici (Turkey)
Editor, *BMJ*

Advisory Committee

W vd Berg (The Netherlands)
S Bombardieri (Italy)
F Breedveld (The Netherlands)
L Crofford (USA)
J-M Dayer (Switzerland)
M Doherty (UK)
M Dougados (France)
J Edmonds (Australia)
P Emery (UK)
D Furst (USA)
S Gay (Switzerland)
J Kalden (Germany)
E Keystone (Canada)
L Klareskog (Sweden)

P Lipsky (USA)
S Lohmander (Finland)
R Maini (UK)
E M Mola (Spain)
H Moutsopoulos (Greece)
J O'Dell (USA)
K Pavelka (Czech Republic)
J Rovensky (Slovakia)
Y Shoenfeld (Israel)
J Smolen (Austria)
W van Venrooy (The Netherlands)
E Veys (Belgium)
A Wiik (Denmark)

Guidelines for Authors and Reviewers

Guidance for authors and reviewers can be found at <http://ard.bmj.com/fora>
All papers must be submitted via Bench>Press at <http://submit-ard.bmj.com>

Disclaimer

Annals of the Rheumatic Diseases is published by BMJ Publishing Group Ltd, a wholly owned subsidiary of the British Medical Association, and the European League Against Rheumatism.

The BMA grants editorial freedom to the Editor of the *Annals of the Rheumatic Diseases*. The *Annals of the Rheumatic Diseases* follows guidelines on editorial independence produced by the World Association of Medical Editors and the code on good publication practice of the Committee on Publication Ethics.

The *Annals of the Rheumatic Diseases* is intended for medical professionals and is provided without warranty, express or implied. Statements in the journal are the responsibility of their authors and advertisers and not authors' institutions, the BMJ Publishing Group Ltd, The European League Against Rheumatism or the BMA unless otherwise specified or determined by law. Acceptance of advertising does not imply endorsement.

To the fullest extent permitted by law, the BMJ Publishing Group Ltd shall not be liable for any loss, injury or damage resulting from the use of the *Annals of the Rheumatic Diseases* or any information in it whether based on contract, tort, or otherwise. Readers are advised to verify any information they choose to rely on.

Subscription Information

See p iv
ISSN 0003-4967 (print); 1468-2060 (online)


Copyright

© 2007 BMJ Publishing Group Ltd and European League Against Rheumatism. All rights reserved; no part of this publication may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, recording, or otherwise without the prior permission of *Annals of the Rheumatic Diseases*

• Authors are required to grant *Annals of the Rheumatic Diseases* an exclusive licence to publish; further details available online at <http://annrheumdis.com/fora/licence.dtl>

• *Annals of the Rheumatic Diseases* is published by BMJ Publishing Group, typeset by The Charlesworth Group, and printed in the UK on acid-free paper by Cambrian Printers Limited, Aberystwyth

• Periodicals postage paid, Rahway, NJ. Postmaster: send address changes to: *Annals of the Rheumatic Diseases*, c/o Mercury Airfreight International Ltd, 365 Blair Road, Avenel, NJ 07001, USA



Most commonly affected appendicular enthesal sites in spondyloarthritis. See p 1553

Editorial

1549 A vital clue to deciphering bone pathology: MRI bone oedema in rheumatoid arthritis and osteoarthritis *F M McQueen*

Review

1553 MRI of enthesitis of the appendicular skeleton in spondyloarthritis *I Eshed, M Bollow, D G McGonagle, A L Tan, C E Althoff, P Asbach, K-G A Hermann*

Extended reports

1560 EULAR evidence-based recommendations on the management of systemic glucocorticoid therapy in rheumatic diseases *J N Hoes, J W G Jacobs, M Boers, D Boumpas, F Buttgerit, N Caeyers, E H Choy, M Cutolo, J A P Da Silva, G Esseleens, L Guillevin, I Hafstrom, J R Kirwan, J Rovensky, A Russell, K G Saag, B Svensson, R Westhovens, H Zeidler, J W J Bijlsma*

1568 Tissue chimerism in systemic lupus erythematosus is related to injury *I C L Kremer Hovinga, M Koopmans, H J Baelde, E de Heer, J A Bruijn, I M Bajema*

1574 Endothelial protein C receptor is overexpressed in rheumatoid arthritic (RA) synovium and mediates the anti-inflammatory effects of activated protein C in RA monocytes *M Xue, L March, P N Sambrook, K Fukudome, C J Jackson*

1581 High-grade MRI bone oedema is common within the surgical field in rheumatoid arthritis patients undergoing joint replacement and is associated with osteitis in subchondral bone *F M McQueen, A Gao, M Østergaard, A King, G Shalley, E Robinson, A Doyle, B Clark, N Dalbeth*

1588 HLA-DRB1*0404 is strongly associated with anticalpastatin antibodies in rheumatoid arthritis *I Auger, C Roudier, S Guis, N Balandraud, J Roudier*

1594 Bone mineral density in patients with hand osteoarthritis compared to population controls and patients with rheumatoid arthritis *I K Haugen, B Slatkowsky-Christensen, R Ørstavik, T K Kvien*

1599 Synovitis detected on magnetic resonance imaging and its relation to pain and cartilage loss in knee osteoarthritis *C L Hill, D J Hunter, J Niu, M Clancy, A Guermazi, H Genant, D Gale, A Grainger, P Conaghan, D T Felson*

1604 Associations between the PTPN22 1858C→T polymorphism and radiographic joint destruction in patients with rheumatoid arthritis results from a 10-year longitudinal study *B A Lie, M K Viken, S Ødegård, D van der Heijde, R Landewé, T Uhlig, T K Kvien*

1610 Comparison of in vitro-specific blood tests with tuberculin skin test for diagnosis of latent tuberculosis before anti-TNF therapy *J Sellam, H Hamdi, C Roy, G Baron, M Lemann, X Puéchal, M Breban, F Berenbaum, M Humbert,*



www.publicationethics.org.uk
This journal is a member of and subscribes to the principles of the Committee on Publication Ethics

Ann Rheum Dis: first published as on 1 December 2007. Downloaded from <http://ard.bmj.com/> on May 12, 2021 by guest. Protected by copyright.

- K Welding, D Salmon, P Ravaut, D Emilie, X Mariette, for the RATIO (Research Axed on Tolerance of Biotherapies) Study Group*
- 1616 Epigenetic regulation of leptin affects MMP-13 expression in osteoarthritic chondrocytes: possible molecular target for osteoarthritis therapeutic intervention *D Iliopoulos, K N Malizos, A Tsezou*
- 1622 Joint-specific hand symptoms and self-reported and performance-based functional status in African-Americans and Caucasians: The Johnston County Osteoarthritis Project *A L Elliott, V B Kraus, F Fang, J B Renner, T A Schwartz, A Salazar, T Huguenin, M C Hochberg, C G Helmick, J M Jordan*
- 1627 A closer look at non-Hodgkin's lymphoma cases in a national Swedish systemic lupus erythematosus cohort: a nested case-control study *B Löfström, C Backlin, C Sundström, A Ekblom, I E Lundberg*
- 1633 Comparison of composite measures of disease activity in an early seropositive rheumatoid arthritis cohort *V K Ranganath, J Yoon, D Khanna, G S Park, D E Furst, D A Elashoff, D Jawaheer, J T Sharp, R H Gold, E C Keystone, H E Paulus, for the Western Consortium of Practicing Rheumatologists*
- 1641 Scleroderma lung study (SLS): differences in the presentation and course of patients with limited versus diffuse systemic sclerosis *P J Clements, M D Roth, R Elashoff, D P Tashkin, J Goldin, R M Silver, M Sterz, J R Seibold, D Schraufnagel, R W Simms, M Bolster, R A Wise, V Steen, M D Mayes, K Connelly, M Metersky, D E Furst, for the Scleroderma Lung Study Group*
- 1648 Henoch-Schönlein purpura in children: an epidemiological study among Dutch paediatricians on incidence and diagnostic criteria *J Aalberse, K Dolman, G Ramnath, R Rodrigues Pereira, J-C Davin*
- 1651 Development and validation of a scale for mouth handicap in systemic sclerosis: the Mouth Handicap in Systemic Sclerosis scale *L Mouthon, F Rannou, A Bérezné, C Pagnoux, J-P Arène, E Foïs, J Cabane, L Guillevin, M Revel, J Fermanian, S Poiraudeau*
- 1656 Microscopic measurement of inflammation in synovial tissue: inter-observer agreement for manual quantitative, semiquantitative and computerised digital image analysis *T Rooney, B Bresnihan, U Andersson, M Gogarty, M Kraan, H R Schumacher, A-K Ulfgren, D J Veale, P P Youssef, P P Tak*

- 1661 Nucleosomes possess a high affinity for glomerular laminin and collagen IV and bind nephritogenic antibodies in murine lupus-like nephritis *J E Mjelle, O P Rekvig, K A Fenton*

Concise reports

- 1669 A modification of the Omeract RA MRI score for erosions for use with an extremity MRI system with reduced field of view *J E Freeston, E Olech, D Yocum, E M A Hensor, P Emery, P G Conaghan*
- 1672 Isolated knee monoarthritis heralding resectable non-small-cell lung cancer. A paraneoplastic syndrome not previously described *F Cantini, L Niccoli, C Nannini, D Chindamo, M Bertoni, E Cassarà, C Salvarani*
- 1675 Baseline serum RANKL levels may serve to predict remission in rheumatoid arthritis patients treated with TNF antagonists *I González-Alvaro, A M Ortiz, E G Tomero, A Balsa, J Orte, A Laffon, R García-Vicuña*
- 1679 Rats and mice immunised with chimeric human/mouse proteinase 3 produce autoantibodies to mouse Pr3 and rat granulocytes *Y M van der Geld, T Hellmark, D Selga, P Heeringa, M G Huitema, P C Limburg, C G M Kallenberg*

Letters

- 1683 Management of treatment resistant inflammation of acute on chronic tophaceous gout with anakinra *D McGonagle, A L Tan, S Shankaranarayana, J Madden, P Emery, M F McDermott*
- 1684 Tumour necrosis factor receptor 2 (TNFRSF1B) association study in Sjögren's syndrome *C Miceli-Richard, P Dieude, E Hachulla, X Puechal, F Cornelis, X Mariette*
- 1685 International survey on the diagnosis and management of gout *M Doherty, T Bardin, E Pascual*
- 1686 Like father, like son *J Lee, P Merry, R Ball, K Gaffney*
- 1688 Hypoglycaemia after initiation of treatment with etanercept in a patient with type 2 diabetes mellitus *E Bonilla, Y Y Lee, P E Phillips, A Perl*

- 1688 Correction